Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


H1 Approvals Seen For Russian, Novavax COVID-19 Vaccines In India

J&J, Pfizer Yet To Begin Local Trials

Executive Summary

Multiple COVID-19 vaccines, including from RDIF and Novavax, could get accelerated approvals in India in the first half of calendar 2021, expanding the range at the country’s disposal. J&J's vaccine is expected to follow although it still hasn’t begun local trials, while Pfizer has temporarily withdrawn an application.

You may also be interested in...

EMA To Advise On Tweaking COVID-19 Vaccines Due To New Variants

Concerns that new or future mutations of the novel coronavirus may reduce the protection offered by existing COVID-19 vaccines have prompted the European Medicines Agency to develop guidance to help vaccine manufacturers who are planning to alter to their products.

EMA: No Application Received For Sputnik V Vaccine

There is considerable confusion over the application system used to file the Russian vaccine for approval in Europe.

Lower Efficacy Rate Of J&J’s COVID-19 Vaccine Presents ‘Messaging Challenge’

While vaccine has efficacy rate of 74% in the US, it completely prevented hospitalizations and deaths, which Fauci says is the most important result from a public health perspective. Vaccine findings cannot be compared given emergence of variants since Moderna and Pfizer conducted their studies, Janssen global head of R&D says.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts